

ACRUX FILES NEW INTELLECTUAL PROPERTY APPLICATION FOR ONYCHOMYCOSIS PRODUCT

Acrux (ASX: ACR) today announced that it had filed a new provisional patent application covering its pipeline product ACR-065 which is targeting fungal infection of the nail bed in toes and fingers (onychomycosis).

The lodgment of this new patent application is an important step in progressing Acrux' product development pipeline, including onychomycosis.

ACR-065 is an improved formulation of the most effective and leading topically applied treatment on the market for onychomycosis, Jublia®, which contains the antifungal agent efinaconazole. Acrux is progressing development and expects to initiate clinical trials in the second half of 2017.

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Onychomycosis

Onychomycosis is a fungal infection of the nail. Fungal infections of the nail are common and difficult to successfully treat. Onychomycosis often causes fingernails or toenails to thicken, discolor, disfigure, and split. Without treatment, the toenails can become so thick that they press against the inside of the shoes, causing pressure, irritation, and pain. Half of all nail disorders are caused by onychomycosis, and it is the most common nail disease in adults. Toenails are much more likely to be infected than fingernails.

In the United States alone over 30 million people are affected by onychomycosis, with approximately 3.5 million prescriptions written annually for these patients.¹ Company reported sales of Jublia - the market leading topically applied product were US\$338 million in 2015.¹ Over the next 10 years, market research estimates anticipate the total onychomycosis market to reach total revenue sales of over \$3 billion in 2022.²

Jublia contains the active ingredient efinaconazole, an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

1. Company sales reports and presentation data for Jublia

2. Dermatophytic Onychomycosis (DO) – Global Data. US Drug Forecast and Market Analysis to 2022. June 2013

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

